Table 3.
Nanoparticle | Application | Drug Loaded on NPs | Radiolabeling Method | Ref. |
---|---|---|---|---|
Dendrimer | Human breast cancer (MCF-7) imaging | Without drug | Chelator-based radiolabeling using HYNIC and stannous chloride (reducing agent) | [58] |
A549 tumor imaging | Without drug | Direct radiolabeling using stannous chloride (reducing agent) | [59] | |
Polymeric Nanoparticles | General biodistribution study | Etoposide | Direct radiolabeling using stannous chloride (reducing agent) | [60] |
Sentinel lymph node | Without drug | Direct radiolabeling using stannous chloride (reducing agent),chelator-based radiolabeling using DTPA | [61] | |
Comparative study using various reducing agents for 99mTc radiolabeling | Without drug | Direct radiolabeling using stannous chloride, sodium dithionite or sodium borohydride (reducing agent) | [62] | |
Imaging of folate receptor overexpressed tumors | Folic acid | Direct radiolabeling using stannous chloride (reducing agent) | [63] | |
Imaging of folate receptor or vascular endothelial growth factor receptor-2 (VEGFR-2) overexpressed tumors | Folic acid (FA) to target folate receptor and K237 (HTMYYHHYQHHL) peptide | Direct radiolabeling using stannous chloride (reducing agent) | [64] | |
General biodistribution study | Gemcitabine | Direct radiolabeling using tricarbonyl kit | [65] | |
Lipid nanoparticles | Imaging of folate receptor overexpressed tumors | Cisplatin and folic acid | Direct radiolabeling using stannous chloride (reducing agent) | [68] |
Bone imaging | Methylene diphosphonate (MDP) | Direct radiolabeling using stannous chloride (reducing agent) | [69] | |
Liposomes nanoparticles | General biodistribution study | Without drug | Direct radiolabeling on the surface of nanoparticles | [71] |
General biodistribution study | Without drug | Chelator-based radiolabeling using 2-Iminothiolane and tricrbonyl kit | [72] | |
Oligomers | Human HepG2 cells targeting | Folic acid | Direct radiolabeling using stannous chloride (reducing agent) | [74] |
Protein nanoparticles (Human Serum Albumin) |
General biodistribution study | Bevacizumab | Direct radiolabeling using tricarbonyl kit | [77] |
General biodistribution study | HPMC, GMN2, GPM2 and GTM2 polymer coating | Direct radiolabeling using stannous chloride (reducing agent) | [78] |